|
|
Article: Abbott Reports Positive Data From Anti-TNF RA Antibody.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Abbott Laboratories released Phase III data for the first time from studies of adalimumab, known as D2E7, which is being developed as the first fully human antibody to fight rheumatoid arthritis.
The positive results regarding both safety and efficacy were presented at the annual meeting of the European League Against Rheumatism in Stockholm, Sweden.
Abbott has filed new drug applications with the FDA and with European regulatory authorities for the drug.
"Both European and U.S. regulatory agencies have officially accepted our submission for review," said Cindy Resman, public affairs manager for Abbott Pharmaceuticals, of ...